Get the Stockscreener App
6.093
1.89%
0.113
Immucell Corp stock is traded at $6.093, with a volume of 4,414.
It is up +1.89% in the last 24 hours and down -10.79% over the past month.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
See More
Previous Close:
$5.98
Open:
$6.0482
24h Volume:
4,414
Relative Volume:
0.17
Market Cap:
$55.06M
Revenue:
$23.84M
Net Income/Loss:
$-3.81M
P/E Ratio:
-12.19
EPS:
-0.5
Net Cash Flow:
$-713.00K
1W Performance:
-0.16%
1M Performance:
-10.79%
6M Performance:
+21.37%
1Y Performance:
+69.25%
1-Day Range:
$6.01
$6.10
1-Week Range:
$5.90
$6.2969
52-Week Range:
$3.34
$7.60
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
6.093 | 55.22M | 23.84M | -3.81M | -713.00K | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immucell Corp Stock (ICCC) Latest News
Identifying reversal signals in ImmuCell CorporationJuly 2025 PreEarnings & Fast Gaining Stock Reports - Newser
Volatility clustering patterns for ImmuCell CorporationJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
ImmuCell Corporation stock volume spike explained2025 Earnings Impact & Community Verified Swing Trade Signals - Newser
Risk adjusted return profile for ImmuCell Corporation analyzedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
What data driven models say about ImmuCell Corporation’s future2025 Price Targets & Technical Pattern Based Buy Signals - Newser
How to manage a losing position in ImmuCell CorporationMarket Trend Report & Free Real-Time Volume Trigger Notifications - Newser
ImmuCell Corporation stock trend outlook and recovery pathJuly 2025 Fed Impact & Stock Portfolio Risk Management - Newser
What moving averages say about ImmuCell CorporationJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
Will earnings trigger a reversal in ImmuCell CorporationQuarterly Market Review & Comprehensive Market Scan Reports - Newser
What momentum shifts mean for ImmuCell CorporationGlobal Markets & Stepwise Trade Execution Plans - Newser
Momentum divergence signals in ImmuCell Corporation chart2025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Advanced analytics toolkit walkthrough for ImmuCell Corporation2025 Dividend Review & Stepwise Trade Execution Plans - Newser
ImmuCell Corporation Shows Early Signs of Technical StrengthWeekly Investment Recap & Weekly Top Gainers Trade List - kangso.co.kr
Exit strategy if you’re trapped in ImmuCell Corporation2025 Risk Factors & Expert Curated Trade Setups - Newser
What the charts say about ImmuCell Corporation todayBear Alert & Low Risk High Reward Trade Ideas - Newser
ImmuCell Corporation (NASDAQ:ICCC) Q2 2025 Earnings Call Transcript - Insider Monkey
Is ImmuCell Corporation reversing from oversold territoryTrend Reversal & Free Safe Capital Growth Stock Tips - Newser
Can ImmuCell Corporation hit a new high this month2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Chart based exit strategy for ImmuCell Corporation2025 Big Picture & Technical Confirmation Alerts - Newser
What recovery options are there for ImmuCell CorporationEarnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
Immucell 2025 Q2 Earnings Remarkable 132.8% Net Income Surge - AInvest
ImmuCell Corp Q2 2025 Earnings: Revenue Reaches $6.4 Million, EPS at $0.06 - AInvest
ImmuCell's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Re-Tain Approval, First Defense Sales, and Inventory Management - AInvest
Earnings call transcript: ImmuCell Q2 2025 sees strong sales growth, stock dips - Investing.com
ImmuCell Q2 Profit Jumps as Margins Rise - The Motley Fool
ImmuCell Posts 18% Gain in Q2 - sharewise.com
ImmuCell Corporation Q2 2025 Financial Results - TradingView
ImmuCell Reports Q2 2025 Financial Results: Product Sales Up 18%, Net Income $502,000 - AInvest
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 - Yahoo Finance
Using Ichimoku Cloud for ImmuCell Corporation technicalsMarket Stability and Long-Term Growth Outlook - Newser
Using R and stats models for ImmuCell Corporation forecasting2025 Short Interest & Fast Gaining Stock Reports - Newser
Using Ichimoku Cloud for ImmuCell Corporation technicals [July 2025 Sentiment]Fast Gain Stock Trading Tips - Newser
ImmuCell Refinances Debt with Maine Community Bank, Improves Financial Stability - AInvest
ImmuCell refinances debt with lower interest rate, extends maturity - Investing.com
ImmuCell Secures Better Terms in $2.3M Debt Deal, Extends Payment Timeline to 2030 - Stock Titan
ImmuCell Corporation stock outlook for YEARFree Risk Controlled Picks With Real Returns - Newser
Immucell ICCC Q2 2025 Earnings Preview Upside Potential from New Immunity Product Innovations - AInvest
What makes ImmuCell Corporation stock price move sharplyShort-Term Support and Resistance Forecast - Newser
Price action breakdown for ImmuCell CorporationPredictive System for Long-Term Stock Forecast - Newser
Using data tools to time your ImmuCell Corporation exitAccurate Forecast System with AI Support - Newser
Signal strength of ImmuCell Corporation stock in tech scannersNear-Term Market Opportunity Forecast Sheet - Newser
ImmuCell Earnings: Animal Health Leader to Reveal Q2 2025 Financial Performance - Stock Titan
Full technical analysis of ImmuCell Corporation stockFree Weekly Setup With 3x Return Potential - Newser
Understanding ImmuCell Corporation’s price movementSecure Entry Point Finder with Analysis - Newser
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):